Skip to content

Bioavailability of Vitamin D(25(OH)D) and Omega-3 Fatty Acid (DHA) Enhanced Chicken

Empowering and Transforming the US Broiler Production for Growth, Profit and Sustainability

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05248737
Enrollment
84
Registered
2022-02-21
Start date
2021-12-04
Completion date
2026-05-30
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition, Healthy

Keywords

Vitamin D, Omega-3 fatty acids

Brief summary

The purpose of the research is to evaluate if chicken or eggs obtained from chickens that are fed a diet that contains omega-3 fatty acids (DHA/EPA), or vitamin D (as 25(OH)D) provides additional health benefits by improving the status of omega-3 fatty acids or 25(OH)D in healthy adults who eat this bioenhanced chicken or eggs.

Detailed description

The 2015-2020 Dietary Guidelines advocate intake of lean proteins (such as chicken and fish) while limiting intake of saturated fat. Chicken contains similar protein to beef or pork but has less saturated fat. However, chicken, like other terrestrial meats, has little omega-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) and relatively little vitamin D. Vitamin D insufficiency is common in the US and globally, and has been linked to a number of adverse health outcomes. Vitamin D is ingested primarily from fortified dairy products, but recent animal studies have increased the D content of pork and beef, and the DHA content of chicken and of eggs produced from bioenhanced chickens. Moreover, sunlight exposure alone can enhance the 25(OH)D content of chicken. Notably, supplemental 25(OH)D is more effective than vitamin D at improving vitamin D status in humans, but little is known about the bioavailability of 25(OH)D or DHA/EPA enhanced chicken (muscle) or in enhanced eggs produced from supplemented chickens.

Interventions

DIETARY_SUPPLEMENTDHA/EPA fortified chicken plus Placebo

For participants who received DHA/EPA fortified chicken

DIETARY_SUPPLEMENTnon-25(OH)D fortified chicken/eggs plus vitamin D3 supplement

Provided to participants in the group where they consumed non-fortified chicken/eggs

DIETARY_SUPPLEMENTnon-DHA bio-enhanced chicken plus supplement DHA Omega-3

Used in the crossover part of the study given to the group who did not received DHA bio-enhanced chicken

DIETARY_SUPPLEMENT25(OH)D bioenhanced chicken and eggs plus placebo

participants will receive 25(OH)D bioenhanced chicken and eggs plus a placebo as a dietary intervention

DIETARY_SUPPLEMENTDietary Supplement: DHA/EPA fortified eggs plus Placebo

For the participants who received DHA/EPA fortified eggs

DIETARY_SUPPLEMENTnon-DHA bio-enhanced eggs plus supplement DHA Omega-3

for the participants who received non-DHA bio-enhanced eggs plus supplement DHA Omega-3

OTHERnon-25(OH)D fortified chicken/eggs plus placebo

Provided to participants in the group where they consumed non-fortified chicken/eggs + placebo pills

Sponsors

Cornell University
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy adults * Non-smoking * Age between 18- 35 yo * Females: premenopausal and not pregnant or lactating * Body mass index (BMI) between 18 - 30 kg/m2. * No preexisting medical complications (such as eating disorders, gastrointestinal disorders, malabsorption diseases, or taking medications known to influence iron homeostasis)

Exclusion criteria

* BMI \<18 or \> 30 kg/m2, * Age \<18 y or \> 50y, * Smoking * Pregnancy, lactating * Have gastrointestinal disorders/malabsorption diseases/dietary restrictions/medication use of medications known to impact DHA/EPA or Vitamin D 25(OH)D absorption * Take vitamin and mineral supplementations

Design outcomes

Primary

MeasureTime frameDescription
Concentration of plasma DHA concentrationsBaseline, and time course of 1 hour, 2 hour, 4 hour and 8 hour post mealMeasuring plasma DHA concentration across different time points to assess DHA bioavailability and absorption
Concentrations of serum 25(OH)D, vitamin D2, vitamin D3, 1,25(OH)2D and 24,25(OH)2D3 and vitamin D binding proteinBaseline, and time course of week 2, week 4, week 6, week 8Measuring serum 25(OH)D concentration across different time points to assess 25(OH)D bioavailability and absorption

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026